Legal & General Group’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $41.6K | Sell |
3,117
-2,837
| -48% | -$37.9K | ﹤0.01% | 2748 |
|
|
2025
Q1 | $60.7K | Sell |
5,954
-26,016
| -81% | -$265K | ﹤0.01% | 2713 |
|
|
2024
Q4 | $506K | Buy |
31,970
+2,855
| +10% | +$45.2K | ﹤0.01% | 2450 |
|
|
2024
Q3 | $1.69M | Hold |
29,115
| – | – | ﹤0.01% | 2045 |
|
|
2024
Q2 | $1.33M | Buy |
29,115
+3,660
| +14% | +$167K | ﹤0.01% | 2099 |
|
|
2024
Q1 | $1.69M | Buy |
25,455
+6,579
| +35% | +$436K | ﹤0.01% | 2003 |
|
|
2023
Q4 | $751K | Sell |
18,876
-50
| -0.3% | -$1.99K | ﹤0.01% | 2308 |
|
|
2023
Q3 | $603K | Buy |
18,926
+830
| +5% | +$26.5K | ﹤0.01% | 2363 |
|
|
2023
Q2 | $727K | Buy |
18,096
+8,549
| +90% | +$343K | ﹤0.01% | 2333 |
|
|
2023
Q1 | $408K | Buy |
9,547
+1,464
| +18% | +$62.5K | ﹤0.01% | 2376 |
|
|
2022
Q4 | $388K | Buy |
8,083
+442
| +6% | +$21.2K | ﹤0.01% | 2397 |
|
|
2022
Q3 | $287K | Buy |
7,641
+752
| +11% | +$28.2K | ﹤0.01% | 2491 |
|
|
2022
Q2 | $190K | Buy |
6,889
+35
| +0.5% | +$965 | ﹤0.01% | 2655 |
|
|
2022
Q1 | $373K | Buy |
6,854
+704
| +11% | +$38.3K | ﹤0.01% | 2475 |
|
|
2021
Q4 | $360K | Buy |
6,150
+6
| +0.1% | +$351 | ﹤0.01% | 2518 |
|
|
2021
Q3 | $243K | Buy |
6,144
+2,519
| +69% | +$99.6K | ﹤0.01% | 2624 |
|
|
2021
Q2 | $154K | Buy |
3,625
+209
| +6% | +$8.88K | ﹤0.01% | 2604 |
|
|
2021
Q1 | $211K | Sell |
3,416
-64
| -2% | -$3.95K | ﹤0.01% | 2447 |
|
|
2020
Q4 | $245K | Buy |
3,480
+2,642
| +315% | +$186K | ﹤0.01% | 2380 |
|
|
2020
Q3 | $32K | Sell |
838
-290
| -26% | -$11.1K | ﹤0.01% | 2827 |
|
|
2020
Q2 | $42K | Buy |
+1,128
| New | +$42K | ﹤0.01% | 2769 |
|